{"id":"W4385644744","doi":"10.1182/bloodadvances.2023010151","title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Genentech; Italfarmaco; Swedish Orphan Biovitrum; Grifols; Actuate Therapeutics; Galecto; Sierra Oncology; Pfizer; Incyte; CTI Biopharma; Bristol-Myers Squibb; Constellation Pharmaceuticals; Acceleron; Astellas Pharma; Ionis Pharmaceuticals; Jazz Pharmaceuticals; Alexion Pharmaceuticals; Karyopharm Therapeutics; National Cancer Institute; Gilead Sciences; Sanofi; MorphoSys; Celgene; AstraZeneca; Amgen","keywords":"Ruxolitinib; Anemia; Myelofibrosis; IC50; Medicine; Pharmacology; Cmax; Potency; Internal medicine; Chemistry; Pharmacokinetics; Bone marrow; Biochemistry; In vitro","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006465087,0.0003013401,0.0004517245,0.0001760756,0.00009461165,0.00003116523,0.00006789222,0.00006192784,0.00007078538],"category_scores_gemma":[0.00002549061,0.0001877223,0.00005396654,0.0006321655,0.00007869083,0.0001794126,0.00003368497,0.0001379591,0.00005880451],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005235692,"about_ca_system_score_gemma":0.00007033338,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003471857,"about_ca_topic_score_gemma":0.00009252498,"domain_scores_codex":[0.9981785,0.00002058837,0.0002852324,0.0005376693,0.000535743,0.0004422946],"domain_scores_gemma":[0.9991914,0.00009307701,0.00009967925,0.0002756103,0.0001557845,0.0001844712],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007769183,0.001263339,0.9866226,0.0001346849,0.0001058812,0.0002053091,0.0004154517,0.00003712559,0.0002102155,0.00005140471,0.0002927688,0.009884322],"study_design_scores_gemma":[0.009628319,0.00428787,0.9482215,0.0008632147,0.0002105833,0.000009087559,0.0003796231,0.000008166488,0.0339296,0.00004777618,0.002116317,0.0002979686],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963855,0.0003748678,0.000002866639,0.001408037,0.00004917814,0.000962363,0.000118924,0.0001066029,0.0005916665],"genre_scores_gemma":[0.9965414,0.0003930386,0.001609797,0.0004863009,0.00008410983,0.000379508,0.0001447737,0.00004364477,0.0003174733],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0384011,"threshold_uncertainty_score":0.7655094,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006939995416863052,"score_gpt":0.2316811282671716,"score_spread":0.2247411328503086,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}